Press Releases
Dec 14, 2015
Summary ToggleIntellia Therapeutics Appoints Caroline Dorsa To Company’s Board Of Directors
Former Chief Financial Officer Brings 30 Years of Business Leadership and Board of Directors' Experience CAMBRIDGE, MASS. – December 14, 2015 — Intellia Therapeutics, Inc., a leading gene-editing company, has named Caroline Dorsa to its Board of Directors .
Dec 1, 2015
Summary ToggleJoint Statement of Intellia Therapeutics & CRISPR Therapeutics: Position Regarding Human Germline Gene Editing
Therapeutic applications of gene editing, including CRISPR/Cas9 and other CRISPR-based technologies, provide an unparalleled opportunity for treating, or even curing, patients with serious genetic disorders. These exciting, recently discovered technologies have the potential to bring new treatments
Sep 30, 2015
Summary ToggleFierceBiotech names Intellia Therapeutics as one of its “Fierce 15” Biotech Companies of 2015
Cambridge, MA – September 30, 2015 – Intellia Therapeutics has been named by FierceBiotech as one of 2015's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. "We're honored to be named to the 2015 "Fierce 15" Biotech
Sep 1, 2015
Summary ToggleIntellia Therapeutics Secures $70 Million in Series B Financing
Funds to Accelerate Discovery and Development of Curative Products Based on CRISPR/Cas9 Gene-Editing Technology Pipeline Primarily Focused on Disorders of the Liver and Blood CAMBRIDGE, Mass., Sept. 1, 2015 – Intellia Therapeutics, a leading gene-editing company focused on the development of
Aug 6, 2015
Summary ToggleIntellia Statement on Germline Editing
In May, both the National Institutes of Health (NIH) and the White House voiced concern over ethical issues associated with using gene-editing technology to alter the human germline. The White House Office of Scientific Assessment further stated that, "the Administration believes that altering the
Apr 22, 2015
Summary ToggleIntellia Therapeutics Announces the Appointment of Dr. Sapna Srivastava as Chief Finance and Strategy Officer
CAMBRIDGE, Mass., April 22, 2015 —Intellia Therapeutics, founded to develop curative medicines utilizing CRISPR/Cas9 technology for gene editing and repair, announced today the appointment of Dr. Sapna Srivastava as Chief Financial and Strategy Officer.
Apr 22, 2015
Summary ToggleIntellia Therapeutics Announces Dr. Jennifer Doudna and Dr. Derrick Rossi to Join Company
CAMBRIDGE, Mass., April 22, 2015—Intellia Therapeutics, founded to develop curative medicines utilizing CRISPR/Cas9 for gene editing and repair, announced today that Jennifer Doudna, PhD, and Derrick Rossi, PhD, will join Intellia as founding members and scientific advisors of the Company. Dr.
Jan 7, 2015
Summary ToggleIntellia Therapeutics, Novartis Form Collaboration to Develop New Cell Therapies Using CRISPR/Cas9 Technology
Five-Year Collaboration Focused on CART and Hematopoetic Stem Cell Applications across a Range of Therapeutic Areas CAMBRIDGE, Mass.—January 7, 2015—Intellia Therapeutics, a leader in the development of therapeutic products using CRISPR/Cas9 technology for gene editing and repair, today announced a
Nov 18, 2014
Summary ToggleIntellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology
Scientific Pioneers, Industry Veterans Advance Company toward IND Filing CAMBRIDGE, Mass.—November 18, 2014—Intellia Therapeutics, a new company formed to develop therapeutic products using CRISPR-Cas9 technology for gene editing and repair, announced today that it has closed a Series A investment
